We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.19B
AUM Growth
-$83.9M
Cap. Flow
-$366M
Cap. Flow %
-11.48%
Top 10 Hldgs %
36.17%
Holding
103
New
17
Increased
19
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$71.8M
2
CNC icon
Centene
CNC
+$35.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$34M
4
GH icon
Guardant Health
GH
+$22.8M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$22.5M

Top Sells

Rank Stock Value
1
PPD
PPD, Inc. Common Stock
PPD
+$41.5M
2
AZN icon
AstraZeneca
AZN
+$33M
3
PODD icon
Insulet
PODD
+$30.9M
4
GILD icon
Gilead Sciences
GILD
+$27.3M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.64%
2 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$166M 5.19%
901,441
-158,190
-15% -$27.2M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$149M 4.66%
1,587,348
– –
OM icon
3
Outset Medical
OM
$74.9M
$148M 4.65%
197,781
-3,066
-2% -$2.34M
LLY icon
4
Eli Lilly
LLY
$1.07T
$121M 3.78%
525,455
– –
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.7B
$109M 3.4%
1,116,004
+60,494
+6% +$5.8M
ABBV icon
6
AbbVie
ABBV
$458B
$104M 3.27%
926,823
– –
RCUS icon
7
Arcus Biosciences
RCUS
$3.57B
$96.1M 3.01%
3,498,260
– –
MYGN icon
8
Myriad Genetics
MYGN
$530M
$94.5M 2.96%
3,089,152
+370,529
+14% +$10.7M
IQV icon
9
IQVIA
IQV
$34.7B
$86.7M 2.72%
357,916
– –
HCA icon
10
HCA Healthcare
HCA
$84.8B
$80.7M 2.53%
390,507
– –
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$76.3M 2.39%
+482,985
New +$71.8M
CNC icon
12
Centene
CNC
$31.3B
$76.2M 2.39%
1,045,473
+511,806
+96% +$35.1M
AVTR icon
13
Avantor
AVTR
$7.81B
$73.8M 2.31%
2,079,657
-150,000
-7% -$4.85M
UHS icon
14
Universal Health Services
UHS
$9.43B
$71.3M 2.24%
487,000
– –
NVRO
15
DELISTED
NEVRO CORP.
NVRO
$69.4M 2.18%
418,645
-26,232
-6% -$4.09M
ACAD icon
16
Acadia Pharmaceuticals
ACAD
$4.25B
$68.5M 2.15%
2,807,310
+1,505,181
+116% +$34M
MCK icon
17
McKesson
MCK
$98.5B
$68.1M 2.14%
356,231
– –
HUM icon
18
Humana
HUM
$46.7B
$63M 1.98%
142,406
– –
UNH icon
19
UnitedHealth
UNH
$382B
$58.2M 1.82%
145,295
– –
EW icon
20
Edwards Lifesciences
EW
$47.6B
$53.1M 1.67%
513,005
– –
ICUI icon
21
ICU Medical
ICUI
$3.93B
$52.6M 1.65%
255,708
-34,953
-12% -$7.19M
DHR icon
22
Danaher
DHR
$135B
$47.1M 1.48%
198,178
– –
GH icon
23
Guardant Health
GH
$19.5B
$46.5M 1.46%
374,131
+169,787
+83% +$22.8M
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$46.4M 1.45%
287,046
-22,734
-7% -$3.65M
GILD icon
25
Gilead Sciences
GILD
$161B
$45.9M 1.44%
666,601
-408,462
-38% -$27.3M
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return

PFM Health Sciences's Q2 2021 Portfolio in Review

As of Q2 2021, PFM Health Sciences held 103 positions worth $3.19B, down 2.6% from $3.27B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $366M in Q2 2021, closing 19 positions and reducing 13 holdings. Its most notable exit was PPD, Inc. Common Stock, an estimated $41.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Seagen Inc. Common Stock worth $76.3M.

  • PFM Health Sciences's largest Q2 2021 buy was Seagen Inc. Common Stock: 482,985 shares worth $76.3M.
  • PFM Health Sciences added most to Centene in Q2 2021, an estimated $35.1M increase.
  • PFM Health Sciences's biggest Q2 2021 reduction was AstraZeneca, cutting an estimated $33M.
  • PFM Health Sciences fully exited PPD, Inc. Common Stock in Q2 2021, selling an estimated $41.5M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $3.19B portfolio in Q2 2021.
  • PFM Health Sciences opened 17 new positions and closed 19 in Q2 2021.
  • PFM Health Sciences's portfolio value fell 2.6% quarter-over-quarter to $3.19B.

Based on PFM Health Sciences's 13F filing for Q2 2021, filed 16 Aug 2021.